| 词条 | Rinucumab |
| 释义 |
| type = mab | image = | alt = | mab_type = | source = u | target = platelet-derived growth factor receptor beta | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 1569263-06-4 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank = | ChemSpiderID = none | C=6472 | H=9974 | N=1710 | O=2022 | S=38 | molecular_weight = 145.3 kg/mol | UNII = 10E3O6YI4W | synonyms = REGN2176 }}Rinucumab (REGN2176) is a monoclonal antibody designed for the treatment of neovascular age-related macular degeneration.[1] This drug was developed by Regeneron Pharmaceuticals, Inc. References1. ^Statement On A Nonproprietary Name Adopted By The USAN Council - Rinucumab, American Medical Association. {{monoclonal-antibody-stub}}{{monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}} 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。